Taken together, these findings indicate that MCPIP1 could serve as a promising biomarker for predicting distant PC metastasis and a target for personalized drug therapy, with the potential to prevent tumor metastasis and improve survival outcomes in patients with cancer. This evidence concerns the gene ZC3H12A and pachyonychia congenita.